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A combination of genetic and immunological features is useful for prediction of autoimmune diabetes.
Patterns of immune response correspond to the progression from a preclinical phase of disease to end-stage
islet damage, with biomarkers indicating transition from susceptibility to active autoimmunity, and to a final
loss of immune regulation. Here, we review the markers that provide evidence for immunological checkpoint
failure and that also provide tools for assessment of individualized disease risk. When viewed in the context
of genetic variation that influences immune response thresholds, progression from susceptibility to overt
disease displays predictable modalities of clinical presentation resulting from a sequential series of failed
homeostatic checkpoints for selection and activation of immunity.Introduction
Progressive immune-mediated loss of insulin-secreting islet
cells leads to type 1 diabetes (T1D). It also leaves a trail marked
by characteristic immunological signs that provide well-vali-
dated predictive markers of disease. The analysis of these immu-
nological markers of autoimmune progression, combined with
measurement of genetic susceptibility traits, leads to a compre-
hensive model of disease pathogenesis. In this model, T1D is the
end result of a sequential series of failed homeostatic check-
points for selection and activation of immunity. Several core
concepts in human autoimmunity are illustrated by these check-
points, which control the likelihood of disease-initiating events,
the transition from autoimmune susceptibility to autoimmune
progression, and ultimately a failure of peripheral immune
regulation.
In this article, we review the immunological markers used
for disease prediction, their interaction with underlying genetic
susceptibility traits, and variables that influence clinical out-
comes. We discuss how these markers provide evidence for
immunological checkpoint failure and how they provide tools
for assessment of individualized disease risk. Some words of
caution are required up front. Current risk estimates represent
extrapolation of findings from model cohorts and studies.
Thus, there are a number of assumptions and caveats in what
is presented. First, much of the data obtained until now has
been on studies of familial cases of T1D, which represent a
minority of all cases. Although there is no evidence that T1D
occurring in the absence of a family history differs with regard
to prediction and pathogenesis, the possibility must be acknowl-
edged. Second, much of what we discuss is derived from what
we know about T1D in children and young adults. A substantial
proportion of patients develop T1D in adulthood, for which the
relationships of disease with genes and immune markers are
much less concrete. We have few biomarkers, and we know little
about pathogenesis. Third, there are critical gaps in our knowl-
edge. We know the major genes and a number of autoantibody
biomarkers, but other biomarkers that could directly reflect path-
ogenesis, such as autoantigen-specific CD4+ and CD8+ effector,
memory, and regulatory T cells, are still unknown or sparsely
applied. In particular, we have limited knowledge in human468 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.subjects about the accuracy of findings in peripheral blood
with respect to the pathology at the pancreas. Despite these
caveats, we hope that the reader will gain an appreciation of
what we believe is an advanced capability to predict T1D, how
current biomarkers relate to models of pathogenesis, and what
gaps and opportunities for further understanding remain.
Biomarkers of Susceptibility: Tools
for Disease Prediction
A portion of estimable genetic risk can be quantified from family
history information and the presence of particular alleles of
the genes that contribute to the familial risk. This risk estimate
can already be determined at or close to birth, both for individ-
uals with and without a family history of disease. Approximately
400 in every 100,000 U.S. children will be born into an already
affected family (Dabelea et al., 2007). These 400 children will
have a T1D risk that exceeds 5%, as compared to around
0.4% in the remaining children. Risk in the 400 children can be
further stratified on the basis of which affected family member
has T1D (3%, 5%, and 8% if they have an affected mother,
father, or sibling, respectively) (Bonifacio et al., 2004; Hemminki
et al., 2009;). Moreover, a minority of such children will have two
affected first-degree relatives and will have a 20% risk.
Much of the familial risk is provided by human leukocyte
antigen (HLA) genotypes. In view of the multiple roles of HLA
genes in T cell selection, antigen presentation, and immune
response, there are many opportunities for HLA-mediated influ-
ences on disease risk and progression. HLA genetic suscepti-
bility clearly influences the types of specificities recognized by
autoreactive T cells, which can be considered the first check-
point in the selection and activation of autoimmunity.
Alleles at the HLA DR and HLA DQ class II loci are the most
useful determinants of inherited risk. T1D risk in a child who
has a T1D sibling can be stratified from 0.3% up to 30% depend-
ing on his or her HLA class II genotype (Schenker et al., 1999; Aly
et al., 2006). Importantly, T1D risk in the children without a family
history of T1D can be stratified from 0.01% to more than 5%
(Emery et al., 2005). Risk can be estimated empirically on the
basis of the frequency of the HLA genotype of the child in
the nondiabetic population and in those who have T1D.
Table 1. Type 1 Diabetes Risk Stratification by T1D Family
History and HLA Genotyping
Population
Type 1 Diabetes
Risk (%)
Low Risk
No affected FDR plus HLA protective genes 0.01
No affected FDR 0.4
Affected FDR plus HLA protective genes 0.3
Intermediate Risk
No affected FDR plus HLA risk genes 4
One affected FDR 5
Mother with T1D 3
Father with T1D 5
Sibling with T1D 8
High Risk
One affected FDR plus HLA high risk genes 10–20
Multiple affected FDRs 20–25
Very High Risk
Identical twin affected 30–70
Multiple affected FDRs plus HLA risk genes 50
Sibling affected plus HLA risk genes,
identical by descent
30–70
FDR, first-degree relative; HLA risk genes, HLA DRB1*03,*04;
DQB1*0302; HLA protective genes, HLA DQB1*0602.
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which confers the highest T1D risk, is present in 2.3% of U.S.-
born Caucasian children and 39% of patients who develop
T1D before age 20 (odds ratio 17), providing a T1D risk of
6.8% (Lambert et al., 2004). The same genotype is present in
7% of the 400 children born with an affected family member,
and therefore risk in the 40 children who have a T1D relative
and have the HLA DRB1*03,*04; DQB1*0302 genotype will be
25%. Extreme T1D risk (up to 50%) will be present in children
with the HLA DRB1*03,*04; DQB1*0302 genotype born into
a family with two or more affected family members (Bonifacio
et al., 2004). Similar extreme risks were reported for children
who are HLA DRB1*03,*04; DQB1*0302 and are identical by
descent to their affected sibling at these loci (Aly et al., 2006).
Finally, T1D is special with respect to genetic susceptibility in
that there are HLA genotypes that confer extreme protection
(Baisch et al., 1990). Thus, T1D risk in a child with a T1D family
history and with protective HLA-DQB alleles, such as HLA
DQB1*0602, is reduced to1% of the risk in children with similar
family history but without this allele. The major classification
categories for T1D genetic risk that are currently clinically prac-
ticable are shown in Table 1, and they illustrate the disparity
between risk for those with and without a family history of T1D.
Alleles at HLA DP class II loci and class I loci, such as HLA
A*24, B*38, and B*39, also contribute to T1D risk, but they
have not been incorporated into risk prediction models. Other
genes or chromosome regions have been shown to confer T1D
risk, but as discussed below, their utility in T1D prediction may
not be high.
The most important change in the T1D risk status of a child
occurs when islet autoantibodies develop. Apart from autoanti-bodies that have been acquired through placental transfer, islet
autoantibodies rarely appear prior to age 6 months (Ziegler et al.,
1999; Naserke et al., 2001). Exceptions include cases of immune
dysregulation, polyendocrinopathy, enteropathy, and X-linked
(IPEX) syndrome in which neonates can develop insulin or gluta-
mic acid decarboxylase (GAD) antibodies in the first months of
life (Rubio-Cabezas et al., 2009). Autoantibodies to four islet
antigen groups have so far been identified: insulin or proinsulin,
GAD65 or GAD67, IA-2 (or ICA512 or IA-2b or PHOGRIN), and
ZnT8 (Palmer et al., 1983; Baekkeskov et al., 1990; Rabin
et al., 1994; Lu et al., 1996; Wenzlau et al., 2007). Antibodies to
other islet antigens exist and contribute to the islet cell antibody
(ICA) staining of the pancreas, but for the purposes of prediction,
the four above mentioned autoantibodies are currently adequate
for T1D that develop in children and young adults (Kulmala et al.,
1998; Bingley et al., 2001; LaGasse et al., 2002). It is noteworthy,
however, that these markers are useful, but insufficient for sensi-
tive prediction of T1D in adults (Bottazzo et al., 2005; Lampasona
et al., 2010). Unlike inherited traits, islet autoantibodies are bio-
markers measured by immunoassay and are therefore defined
by a quantifiable signal. Thus, our accuracy in identifying true
disease-relevant signals will depend upon the quality of the
assay. Because of the consequences associated with labeling
a child as ‘‘islet autoantibody positive,’’ substantial efforts in
standardizing and harmonizing assays for islet autoantibody
measurement have occurred (Bingley et al., 2003; Achenbach
et al., 2007). In this regard, T1D risk estimation is advanced in
comparison to other autoimmune diseases.
The presence of autoantibodies to just one of the four antigen
groups alone is associated with only a marginal increase in risk,
both in subjects with and without a family history of T1D, indi-
cating that with current assays and threshold for positivity, auto-
antibodies to single islet antigens are not rare. Thus, current
assays probably include a variable component of non-specific
binding, and an important checkpoint in disease is progression
to the multiple islet autoantibody stage. T1D risk is, indeed,
markedly increased when islet autoantibodies to two or more
of the antigen groups are found in a child (Bingley et al., 1994;
Verge et al., 1996; Achenbach et al., 2004b). Risk is incremental
in relation to whether antibodies are against two, three, or four of
the antigen groups and among those without the full comple-
ment of four islet autoantibodies. T1D risk can vary in relation
to which of the islet autoantibodies is present (Achenbach
et al., 2004b; Achenbach et al., 2006; Achenbach et al., 2009).
In particular, the presence of antibodies to IA-2 (or ICA512 or
IA-2b or PHOGRIN) is associated with highest risk. Similar to
the number of islet autoantibodies, greater titer, affinity, and
broadness of epitope reactivity are features of islet autoanti-
bodies that are associated with high T1D risk. In other words,
the more islet autoantibodies one has and the stronger they
are, the higher the T1D risk.
Islet autoantibodies can be transient (Yu et al., 2000), but high-
titer islet autoantibodies to multiple islet antigens rarely if ever
completely disappear prior to diabetes onset. Nevertheless,
repeated testing of islet autoantibodies in positive cases is
valuable in order to determine whether more antibodies have
developed.
T1D risk is a combination of the likelihood of disease develop-
ment and the rate at which it will develop. Importantly, it is anImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 469
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Figure 1. Individual Stratification for Diabetes Risk Reflects Stages
of Disease Progression
The following abbreviations are used: GAD, glutamic acid decarboxylase; IA-2,
islet-associated autoantibody 2; ZnT8, zinc transporter 8; IVGTT, intravenous
glucose tolerance test; OGTT, oral glucose tolerance test; and HbA1c, hemo-
globin A1c.
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within days of being identified as islet autoantibody positive,
whereas others will take decades to develop disease and
some not at all.
Considerable effort has been made to determine risk on the
basis of genes, autoantibodies, and age and to stage the predi-
abetes period with markers of beta cell function, as illustrated
in Figure 1. Various combinations of the risk markers can give
similar overall risk, and for most combinations the risk can be
calculated empirically. Risk can be stratified from <1% to >70%
(Figure 2). Current approaches use a stepwise decision tree.
Genetic risk is usually the first marker applied in the form of family
history and/or HLA class II genotype. Autoantibodies are selec-
tively measured in those individuals who are considered to have
sufficient genetic risk to warrant autoantibody testing. Islet auto-
antibody screening in genetically at-risk children is worthwhile
from the age of 1 year. Further genetic typing may be applied
in autoantibody-positive individuals to exclude those with
protective HLA class II genotypes. Finally, beta cell function is
measured in islet autoantibody-positive individuals using either
the ability of the beta cell to secrete insulin in response to an
intravenous glucose challenge or the ability of the individual
to clear glucose after a meal challenge (Srikanta et al., 1985).
More recently it has also been recognized that insulin demand
from the body is also likely to affect the timing of clinical diabetes
(Fourlanos et al., 2004), and a global measure of insulin produc-
tion together with insulin sensitivity may be a better measure of
beta cell function for the purposes of T1D prediction.
Working our way down this decision tree provides a manner to
select individuals who have sufficient risk to warrant inclusion
into intervention trials. The risk that is considered sufficient will
depend upon the toxicity and invasiveness of the intervention
therapy applied. For the future, it could be expected that once
effective preventative therapies become available, the decision
tree approach will be replaced by the population-wide applica-
tion of all the above markers in a public-health-prevention man-470 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.ner. In such an approach, the stepwise algorithms are likely to
be replaced by a risk score, based on the combination of all
markers, representing a paradigm shift after years of increasingly
complex layers of decisions in screening.
Because the determination of T1D risk of an individual
depends on family history and on autoantibody status, it neces-
sarily follows that risk estimates can change throughout life.
For example, predictive risk for a child who has no family history
of T1D at birth increases by a factor of ten if his or her sib-
ling develops T1D, and if the child has an identical twin who
develops T1D, predictive risk will increase dramatically to
50% (Redondo et al., 2008). Risk calculated from the autoanti-
body status will usually increase over time as autoantibodies
appear and their number rises. The relationship between age
and T1D risk is complex. The risk of developing islet autoanti-
bodies is high early in life as compared to late (Bingley, 1996).
Moreover, the earlier autoantibodies appear, the faster the rate
of progression to diabetes (Hummel et al., 2004). This may reflect
a more aggressive or less regulated immune response, or it may
be partially related to beta cell function and insulin demand of
the body.
Genotypic Variation Influences Immunological
Thresholds for Selection and Activation
The current technologies for identifying T1D risk are generally
highly specific for the high-risk categories of individuals, but
have low overall sensitivity in the general population, given that
most cases of T1D arise in populations with low to moderate
levels of overall risk. Prospects for filling some of the gaps rely
on the development and appropriate use of additional genetic
and immunological markers that involve alterations in immune
response pathways implicated in disease. These additional
biomarkers may be either dependent or independent of HLA-
associated events, and others may target general pathways of
immune activation.
There are two additional genetic loci commonly associated
with a relative risk for T1D > 2.0, INS and PTPN22 (Concannon
et al., 2009). Recent studies now provide insight into how these
genes influence the underlying HLA-associated disease risk.
Allelic variation at INS, the gene encoding proinsulin, confers
differential susceptibility to T1D: variation in INS is categorized
by polymorphisms in a VNTR element, associated with an
odds ratio for T1D susceptibility of 2.2 in INS VNTR I subjects
relative to the heterozygous or ‘‘protective’’ INS VNTR III geno-
types (Bennett et al., 1995). The INS VNTR III genotype is asso-
ciated with high expression of thymic proinsulin in thymic medul-
lary epithelial cells, suggesting a correlation between antigen
level and negative selection of high-avidity autoreactive T cells,
consistent with a prominent role for central tolerance in protec-
tion from insulin autoimmunity (Pugliese et al., 1997; Vafiadis
et al., 1997). This hypothesis has been directly tested with proin-
sulin tetramers to profile T cells from genetically disparate
subjects, and have shown that the expression of high-avidity
T cell receptor (TCR) specific for the dominant proinsulin epitope
PI76-90 is under genetic control. Comparison of peripheral
blood lymphocytes in HLA DRB1*04 subjects showed that 79%
of INS VNTR I,I subjects had detectable proinsulin tetramer-
positive T cells, compared with 29% of the INS VNTR III subjects
(p < 0.0007) (Durinovic-Bello´ et al., 2010).
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Figure 2. Type 1 Diabetes Risk
Stratification by Islet Autoantibody
Properties
Increase in T1D risk is associated with progression
of islet autoantibodies from single to multiple auto-
antibodies. Characteristics of the initial antibody
response can help predict disease progression.
The following abbreviations are used: IAA, insulin
autoantibodies; GAD65, glutamic acid decarboxy-
lase 65; IA-2, islet-associated autoantibody 2; and
ZnT8, zinc transporter 8.
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assays (Durinovic-Bello´ et al., 2002), proinsulin autoantigen-
specific CD4+ T cells are present in both normal and T1D
subjects (Yang et al., 2008). The frequency of these cells is
low, estimated to range from 1:30,000 to 1:200,000 in peripheral
blood samples. For distinguishing between high-avidity and low-
avidity T cell receptors specific for proinsulin, tetramers were
created with agonist peptides containing amino acid substitu-
tions in the PI76-90 epitope, which improve binding of the
tetramer to the antigen-specific TCR; substitution of lysine to
serine at peptide position p9 generates superagonist variant
PI76-90S88, resulting in enhanced detection of a low-avidity
proinsulin-positive CD4+ T cell population (Yang et al., 2008).
In contrast to the results cited above, when the same T cell
samples were analyzed with the variant PI76-90S88 tetramer,
there was no difference in tetramer-positive cells detected
between the INS VNTR groups (Durinovic-Bello´ et al., 2010).
Thus, low-avidity anti-proinsulin T cells are present independent
of genotype, whereas the presence of anti-proinsulin T cells with
higher avidity is under INS genetic control. This illustrates an
early and primary checkpoint for autoreactivity that influences
the frequency and avidity of the T cell repertoire. The genetic
association between INS polymorphisms and T1D disease
frequency, even among individuals identical for high-risk HLA
genes, suggests that the threshold for autoimmune predisposi-
tion is sensitive to modulation and is likely to be an important
determinant of subsequent disease progression.
Lessons from PTPN22: Variation in Immune
Activation Checkpoints
Genetic variation in the protein tyrosine phosphatase N22
(PTPN22) is associated with T1D, as well as with other autoim-
mune diseases, including rheumatoid arthritis, systemic lupus
erythematosus, Graves disease, and myasthenia gravis (Bego-
vich et al., 2004; Bottini et al., 2004; Kyogoku et al., 2004; Onen-
gut-Gumuscu et al., 2004; Smyth et al., 2004; Velaga et al., 2004;
Ladner et al., 2005; Vang et al., 2005; Harley et al., 2008).
Biochemical studies of the PTPN22-encoded protein variantsImmunityhave demonstrated an increase in phos-
phatase function associated with the
disease-associated sequence, which, in
the context of TCR activation, decreased
signal transduction. Direct studies of
human peripheral blood mononuclear
cells (PBMCs) from subjects differing at
PTPN22 have confirmed that the dis-
ease-associated variant is a gain-of-function variant that leads to a blunting of both the BCR and
the TCR signal upon stimulation (Rieck et al., 2007). In CD4+
T cells, this phenotype is characterized by diminished calcium
flux upon TCR stimulation and diminished downstream expres-
sion of activation markers and cytokines. Interestingly, there is
also an alteration in the percentage of memory CD4+ T cell
composition of the T cell compartment, suggesting increased
survival of effector memory cells in the context of the disease-
associated variant, perhaps as a result of impaired activation-
induced cell death (AICD) signaling. Similar functional variation
is seen in human B cells. Calcium flux after B cell receptor
(BCR) stimulation was reported to be diminished in the B cells
of individuals with the PTPN22 variant, as was phosphorylation
of Syk kinase, phospholipase Cg (PLCg), and AKT kinase
(Arechiga et al., 2009). B cell maturation involves progression
through a series of checkpoint controls, so it is possible that
the impaired signaling allows for persistence or redirection of
less mature, more polyreactive phenotypes associated with
autoimmunity.
The HLA, INS, and PTPN22 genetic associations with T1D
illustrate the cardinal features of autoimmune predisposition:
establishing a lowered threshold for selection and activation of
autoreactive T cells that varies among individuals, based on
genotype. As demonstrated by the proinsulin tetramer studies
cited above, one consequence of this genetic programming is
manifest through the level of high-avidity autoreactive cells in
the peripheral circulating immune repertoire. As indicated by
the PTPN22 studies, disease pathogenesis is then influenced
by variable activation thresholds related to autoimmune pro-
gression. There are important implications of these observations
for T1D prediction because it may be possible to determine the
likelihood of disease progression, separate from the primary
biomarkers that are used to predict initial risk. Examples that
shine a light on this gray area of disease prediction and suggest
pathogenic mechanisms include the following:
T1D autoantigen-specific T cells from normal subjects are
predominantly CD45RA+, indicating a naive phenotype, for
both GAD65 (Danke et al., 2005; Monti et al., 2007) and for32, April 23, 2010 ª2010 Elsevier Inc. 471
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perienced with respect to antigen and probably represent
a potential autoimmune repertoire, which has not been activated
in vivo. In contrast, the autoantigen-specific T cells from T1D
subjects and at-risk relatives are both CD45RA+ and CD45RA-
RO+, the latter representing a memory phenotype indicating prior
antigen experience (Danke et al., 2005; Monti et al., 2007). This is
consistent with the presence of islet autoantibodies in most such
subjects, driven by T cell-dependent help.
When memory T cells are chronically activated, they are
known to undergo maturation of several functional markers;
one of these, Kv1.3, is a potassium channel upregulated in
effector memory responses. GAD65-specific CD4+ T cells from
T1D subjects, but not from nondiabetic individuals, display
a Kv1.3-high phenotype (Beeton et al., 2006).
Another feature, which is an indicator of recurrent in vivo stim-
ulation, is evidence of avidity maturation of the T cell response.
Avidity maturation is the transition of a population of polyclonal
T cells into a mature set of oligoclonal T cells, which have high
avidity for a specific target antigen. This occurs in vivo in the
setting of chronic exposure to low doses of antigen and has
been seen in GAD-specific CD4+ T cells in association with
T1D (Bielekova et al., 2004; Standifer et al., 2009). This has
been more extensively studied in the context of multiple scle-
rosis, in which Martin et al. have shown that high-avidity autoan-
tigen-specific T cells are enriched for previously in vivo, activated
cells and are significantly skewed toward a proinflammatory
phenotype (Muraro et al., 2000; Bielekova et al., 2004).
Overall, then, the number and ratio of high- to low-avidity
autoreactive cells in the developing immune system is a function
of genes that control TCR engagement and lymphocyte matura-
tion, most notably HLA molecules, but also including modifiers of
T cell activation. Subsequent events that result in chronic antigen
exposure—either damage to the islet cells from pathogens or
toxins, or genetically influenced beta cell death from natural
causes—may very well be the source of the antigen-specific
stimuli, which trigger the transition seen when T cells evolve
from naive to memory markers. In this scenario, a second check-
point regulates the persistence and maturation of autoreactive
cells (a marker of disease progression), subsequent to the first
checkpoint that establishes the autoreactive repertoire (a marker
of underlying disease risk). People with a high genetic load
subsequently carry a higher frequency of autoreactive T cells,
and therefore they have a lower threshold for autoimmune acti-
vation when islet cell damage and antigen exposure occurs.
Clinically this may account for earlier age of disease onset or
for a higher overall prevalence of disease and is reflected in
the measurement of high titer serum autoantibodies. Conversely,
people with a low genetic load and low numbers of autoreactive
T cells have a higher threshold, and such cells delay the transi-
tion to effector memory responses or require larger amounts of
antigenic challenge to trigger disease progression. The pheno-
typic properties of the effector memory population outlined
above suggest that after a particular frequency of autoreactive
T cells is established, the transition from a highly susceptible
stage of preclinical risk to a progressive disease stage leading
to T1D in this model is represented by the accumulation of
high-avidity memory effector cells with autoantigen specificity.
Whether measuring this transition will be useful in predicting472 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.disease in the low-to-moderate risk HLA cohorts remains to be
determined.
Additionally, the link between these phenotypic properties
of peripheral lymphocytes and the activity of autoreactive cells
in the local environment of pancreatic islets and draining
lymph nodes is unclear. This question currently represents
a deep knowledge gap between the biomarker studies and the
presumed role of tissue damage and antigen exposure in
pathogenesis.
Other Potential Biomarkers for T1D Prediction
There are complex interconnections of innate and adaptive
immunity and with the tissue response to autoimmune attack,
which undoubtedly changes during the progression from dis-
ease risk to overt diabetes. In an attempt to detect these
changes, a number of ‘‘next generation’’ technologies are being
explored for their capacity to find biomarkers that will improve
disease prediction. Because of the large number of unknowns
associated with the complex immunobiology of progressive
autoimmunity, these new approaches have used unfocused
screening methods to uncover potential molecular candidates.
One example is the use of transcript array analysis of whole-
blood samples or of circulating PBMCs. This work is based on
prior success with another autoimmune disease of children,
systemic onset juvenile idiopathic arthritis (SOJIA). In SOJIA,
a prominent set of transcripts collectively induced by inter-
leukin-1 (IL-1) was identified as a biomarker of active disease
(Allantaz et al., 2007). On the basis of the array findings, a clinical
trial of IL-1 blockade was initiated and rapidly led to its adoption
as a therapy of choice for this patient group (Pascual et al., 2008).
A similar pilot study in T1D found a set of transcript markers
associated with inflammation and hyperglycemia, but did not
pinpoint any T1D-specific expression signatures (Chaussabel
et al., 2008). A second example used serum from T1D subjects
to elicit novel transcript responses from a standardized cell
line, detected on large scale arrays. Again, there was prior prece-
dent for this type of study, which had been used successfully to
identify type I interferons (IFNs) as a prominent bioactive medi-
ator in systemic lupus erythematosus (SLE) (Chaussabel et al.,
2008). In these SLE studies, serum from patients taken prior to
therapy elicited a type I interferon transcript profile, an effect
neutralized by adding anti-IFN Ab or by treatment of the patients
to induce clinical remission. Although an initial report with
a similar approach in T1D suggested the possibility of an IL-1-
associated profile (Wang et al., 2008), this is currently a disputed
area of investigation without a clear outcome (Jackson et al.,
2008; Bergholdt et al., 2009). A third example is the application
of a metabolomic analysis. Metabolite biology in the serum
reflects a network of interactions, manifest as a complex and
heterogeneous chemistry. A preliminary report of a potential
marker for early T1D disease risk has been published, in which
lipid mediators associated with inflammation were reportedly
present prior to the detection of specific anti-islet autoantibodies
(Oresic et al., 2008).
Pathogenesis and Disease Progression
T1D can occur in the context of widespread autoimmune dysre-
gulation, such as within the IPEX or APS1 syndromes as a result
of mutations in the forkhead box P3 (FOXP3) and autoimmune
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the BABYDIAB study population; abbreviations as in legend to Figure 2.
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Reviewregulator (AIRE) genes, respectively (Wildin et al., 2001; Turunen
et al., 2006), but the vast majority of patients with autoimmune
diabetes do not have globally dysregulated immunity and
instead follow a fairly restricted and targeted immunological
path. There are two characteristics of T1D present in most
patients, namely at least one susceptible HLA class II haplotype
and islet autoantibodies. Thus, regardless of the etiological
factor(s) that may favor the development of islet autoimmunity
in a child, it remains highly probable that the initiation of the
disease process is the effector immune response to islet beta
cell antigens and that the appearance of islet autoantibodies is
our first detectable sign of this process.
Islet autoantibodies rarely appear prior to approximately age 6
months, and among children with a family history of T1D there is
a peak incidence at approximately 1 to 2 years of age (Naserke
et al., 1999; Hummel et al., 2004; Bonifacio et al., 2008). This is
a relatively important observation because, in terms of the dis-
ease process, it suggests that the events leading to islet autoim-
munity are encountered after 6 months of age and potentially
at increased frequency in early infancy and/or that neonatal
immune mechanisms are relatively protective from disease
during the first six months of life. Islet autoantibodies that appear
in the 1 to 2 year age period have certain characteristics.
Antibodies to the insulin or proinsulin antigen group are often
among the first to appear (Hummel et al., 2004), and within
pre-type 1 diabetes children, they have a strong association
with HLA DRB1*04; DQB1*0302 (Ziegler et al., 1991). Thus,
HLA DRB1*04; DQB1*0302-associated immune activation of
insulin reactive B and T cells is a frequent characteristic of the
initial disease process of childhood diabetes. The insulin autoan-
tibodies (IAAs) are of high-affinity IgG1 class already at first
detection, suggesting rapid affinity maturation (Castan˜o et al.,
1993; Bonifacio et al., 1999; Achenbach et al., 2004a). IgM-IAA
is rarely observed (unpublished data). Spreading of the immune
response to other islet antigens is frequent. The high-affinity IAA
almost always bind strongly to both insulin and proinsulin
(Achenbach et al., 2004a) and can also bind the intermediate
products desmin (DES)-(31-32)-proinsulin and DES-(64-65)-
proinsulin that are found within insulin secretory granules. These
IAAs probably recognize a common epitope. Although this
insulin or proinsulin start and spread of autoimmunity to disease
is common in this 1 to 2 year appearance group, other immuni-
zation profiles occur. There is an acute, ‘‘explosive’’ antibody
response to all antigen groups with rapid progression to disease,
suggesting uncontrolled rapid beta cell destruction. In addition,
some children progress to diabetes after developing a high-
affinity autoantibody response to GAD65 prior to IAA. In con-
trast, antibodies to IA-2, IA-2b, and ZnT8 antigen groups very
rarely appear on their own or prior to IAA or GAD antibodies
(Achenbach et al., 2009). Whether the ’’insulin,’’ ’’GAD,’’ and
‘‘explosive’’ antibody phenotypes of pre-type 1 diabetes simply
represent immune response gene-associated variants or are
consequences of different etiology is unknown.
The relatively homogeneous autoantibody profile found in a
sizable proportion of children who develop diabetes in childhood
is potentially informative with respect to pathogenesis. First,
the major targets are preferentially or exclusively expressed in
the beta cell. Second, the ubiquitous beta cell proteins, such
as actin and nuclear proteins often targeted in systemic autoim-mune diseases, are not prominent autoantigens in T1D. Third,
there are particular HLA associations seen with specific autoan-
tibody responses (Graham et al., 2002; Mayr et al., 2007; Achen-
bach et al., 2009). Fourth, in the case of the beta cell-specific
ZnT8 antigen, there is an exquisite specificity of autoantibodies
to self-polymorphic variants of the protein. ZnT8 residue 325
lies within a major epitope of ZnT8 autoantibodies (Wenzlau
et al., 2007; Achenbach et al., 2009). Children who are homozy-
gous for the 325R variant make antibodies to the epitope that
expresses 325R and not to the epitope expressing 325W, and
vice versa, suggesting autoimmunization as a result of physio-
logical beta cell death or an event associated with induced
beta cell death, e.g., cytopathic virus. In either case, the precise
target specificity of the response is likely to be favored by protein
abundance in the beta cell, location within secretory structures,
and preferential presentation of its peptides by the T1D-associ-
ated HLA class molecules. The right constellation to reach the
threshold needed for a sustained effector immune response is
likely to also include alleles at other immune response genes
that lower immune activation threshold and an inflammatory
cytokine milieu.
Although childhood diabetes is characterized by early appear-
ance of autoantibodies, autoimmunization can occur at any time
during life. Observations from the German BABYDIAB cohort
(children of parents with T1D) show a second peak incidence
period around puberty (Figure 3). The characteristics of the islet
autoantibody profiles seen in ’’late’’ autoantibody-positive
children are heterogeneous, and the typical profile is different
compared to that seen in the 1 to 2 year olds. AutoantibodiesImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 473
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spreading to other islet proteins, is common. Lower-affinity IAAs
or GAD65 antibodies are also more common, as are antibodies
directed against atypical epitopes. Whereas early autoantibody
development is strongly linked to T1D-associated HLA class II
genotypes, the distribution of HLA class II genotypes in children
who develop islet autoantibodies late is less dominated by HLA
DRB1*04; DQB1*0302 genotypes. One interpretation of the
differences associated with age of islet autoantibody appearance
is that etiology and immunization are truly different; i.e., events
that lead to an insulin-dominant spreading autoimmunity at age
1 year are different from those that lead to a GAD65-restricted
autoimmunity at age 11 years. Alternatively, immune activation
thresholds differ with age, perhaps influenced by genetic varia-
tion, as a result of environmental exposures that condition and
program memory and regulatory immune responses. This trend
toward less HLA dominance and more heterogeneous antibody
profiles is also pronounced in older individuals developing auto-
antibodies who lack a family history of T1D.
Assigning etiological causation to environmental triggering
factors for islet autoimmunity remains a challenge. A major histo-
compatibility complex (MHC)-dominated process appears to be
operating at very young age, so that environmental agents that
favor (or protect from) T1D do so in an MHC-dependent manner.
There are no consistent findings of single agents that account for
the majority of children in which early islet autoimmunity occurs,
and proposed mechanisms are speculative and not entirely
consistent with the autoantibody appearance findings described
above. An intriguing possibility is that immune response thresh-
olds for islet autoimmunity during childhood are programmed
during fetal life. Evidence in type 1 diabetes includes the obser-
vations that exposure to elevated blood glucose levels and
maternal islet autoantibodies during a diabetic pregnancy are
associated with reduced risk of islet autoantibodies in the child
(Bonifacio et al., 2008). An ongoing study, called The Environ-
mental Determinants of Diabetes in the Young study (Hagopian
et al., 2006), is designed to address some of the proposed envi-
ronmental associations.
There is no typical progression from the appearance of islet
autoantibodies to clinical diabetes. It can be a matter of weeks
to decades. By analogy with other autoimmune disorders, a
shorter preclinical course most likely indicates aggressive, sus-
tained islet beta cell destruction, whereas decades could repre-
sent a series of waxing and waning episodes of beta cell destruc-
tion or a constant slow beta cell loss. Notably, the observation
that autoantibody responses ‘‘spread’’ to new islet antigens
and epitopes at irregular intervals strongly suggests that active
immunization is occurring at several occasions during the predi-
abetic period (Bonifacio et al., 1999). Finally, although measure-
able loss of beta cell function is a biomarker of impending clinical
disease, some islet autoantibody-positive subjects can stay at
a low level of insulin production for years prior to clinical disease.
These observations are most consistent with the notion that
immunologically mediated beta cell destruction is under some
sort of regulatory control, as discussed below.
The Final Checkpoint: Regulatory Failure in T1D
Many individuals with the immunological markers of pre-clinical
T1D do not progress to clinical disease. An attractive hypothesis474 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.is that individuals who have islet autoantibodies and suscepti-
bility genes, but who do not progress to T1D, may be the bene-
ficiaries of a successful regulatory immune response. A great
deal of attention has therefore been focused on the analysis of
immunoregulatory function associated with T1D autoimmunity,
based on the likelihood that a failure of immune regulation is
required for complete immune-mediated beta cell loss.
A number of contradictory observations confound this
field, however. Regulatory T cell numbers have variously been
reported to be decreased or normal in T1D (Lindley et al., 2005;
Putnam et al., 2005; Tree et al., 2006; Brusko et al., 2007; Oling
et al., 2007; Yang et al., 2007; Link et al., 2008; Vrabelova et al.,
2008; Grant et al., 2009; Luczyn´ski et al., 2009), and functional
assays have similarly described low, slightly decreased, or normal
regulatory activity (Lawson et al., 2008; Schneider et al., 2008; Jin
et al., 2009; Long et al., 2009, 2010; Putnam et al., 2009; Ryden
et al., 2009). Much of this muddle is probably due to methodolog-
ical differences in various laboratories, given that the precise
definition of human regulatory T cells has changed several times
in recent years, and most of these studies have not distinguished
between potentially distinct regulatory T cell subsets.
Nevertheless, a consensus is developing regarding a few key
points: First, there is clear evidence for the existence of natural
regulatory CD4+CD25+FOXP3+ T cells in both pre-T1D and post-
diagnosis T1D subjects. Similarly, precursor cells are present,
which can readily be induced to form CD4+FOXP3+ T cells with
in vitro regulatory function (Putnam et al., 2009). Second, some
of these induced Treg cells display antigen specificity for islet
autoantigens and appear indistinguishable from similar cells
from non-T1D subjects (Long et al., 2010). Third, various proto-
cols to expand CD4+CD25+FOXP3+ cells have been successful
both in vitroand in vivo, particularly aided by the use of rapamycin,
which, in addition to its therapeutic implications, unequivocally
demonstrates the presence of these cells in T1D subjects (Batta-
glia et al., 2006; Monti et al., 2008). An analogous situation may
exist with CD8+ regulatory T cells as well, unmasked after therapy
of T1D subjects with anti-CD3 mAb (Bisikirska et al., 2005).
Alternatively, when natural or induced regulatory T cells are
tested for suppressive function on autologous CD4+ effector
T cells, T1D subjects generally show diminished regulatory
activity compared with non-T1D controls (Lindley et al., 2005;
Schneider et al., 2008). This now appears to be, at least in
part, due to a distinct phenotype ascribed to the effector T cell
population in T1D—namely, that these cells are somewhat
refractory to the regulatory control of CD4+CD25+FOXP3+ Treg
cells. In a study of HLA-matched control and T1D subjects,
regulatory cells from T1D subjects or those from control subjects
showed comparable suppression of effector T cells from the
controls, whereas neither was effective at suppression of effec-
tor T cells from the T1D subjects (Schneider et al., 2008).
The molecular mechanism accounting for this refractory effector
cell phenotype is unknown.
Two biomarkers have been proposed as potential surrogates
for predicting immune regulatory status in the context of disease
prediction. HLA-DQB1*0602 is an MHC class II allele, which is
negatively associated with T1D in population studies, even in
individuals heterozygous for one of the major HLA T1D-associ-
ated genes (Baisch et al., 1990). Further, the rare T1D subject
who does carry DQB1*0602 tends to develop disease at a later
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Reviewage, even in subjects who are positive for T1D autoantibodies
(Pugliese et al., 1995; Sanjeevi et al., 1995). This dominant pro-
tection is strongly suggestive of a regulatory protection mecha-
nism favoring disease remission, although the molecular and
cellular mechanisms remain to be defined. The other potential
regulatory biomarker is also a genetic trait, a polymorphism in
the PTPN2 gene. This gene encodes a phosphatase that has
widespread functions in many cell types, but in particular is crit-
ically involved in signaling of cytokines, such as IL-2 and IL-15.
The T1D-associated variant of PTPN2 leads to diminished
phosphorylation of STAT5 in T cells, interfering with cytokine
signaling, raising the possibility that this variant may interfere
with Treg cell survival, which is highly dependent on IL-2 activity
(Long et al., 2009).
Concluding Remarks
More than any other common autoimmune disease, childhood
and early adult T1D is now partially predictable in genetically
susceptible individuals by careful use and analysis of genetic
and immunological biomarkers. Utilizing these predictive tools
on a broad scale requires two major advances: First, the devel-
opment of simple, inexpensive, point-of-use technologies suit-
able for widespread clinical use; second, the clinical rationale
for intervening therapeutically in individuals who are at high dia-
betes risk. This latter clinical impetus will come when treatments
capable of halting disease progression are shown to be safe and
effective, a goal that currently drives many ongoing clinical trials
in T1D. In the meantime, T1D prediction studies in large popula-
tions can help us refine our view of pathogenesis, by linking
genetic variation with particular molecular and cellular mecha-
nisms and perhaps by identifying individuals, who, in cases of
slow disease progression, help us identify physiological mecha-
nisms of successful immunoregulation.
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